Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

N4 Pharma Plc (N4P) Share Price

Price 0.525p on 09-05-2025 at 11:05:42
Change 0.015p 2.94%
Buy 0.55p
Sell 0.50p
Buy / Sell N4P Shares
Last Trade: Buy 18,975.00 at 0.527p
Day's Volume: 1,089,779
Last Close: 0.51p
Open: 0.51p
ISIN: GB00BYW8QM32
Day's Range 0.51p - 0.525p
52wk Range: 0.375p - 0.80p
Market Capitalisation: £4m
VWAP: 0.518096p
Shares in Issue: 832m

N4 Pharma Plc (N4P) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 18,975 0.527p Ordinary
12:05:41 - 09-May-25
Buy* 363 0.55p Ordinary
11:58:31 - 09-May-25
Sell* 34,750 0.505p Ordinary
11:37:57 - 09-May-25
Sell* 50,000 0.524p Ordinary
11:24:00 - 09-May-25
Sell* 100,000 0.519p Ordinary
11:21:25 - 09-May-25
Sell* 20,000 0.50p SI Trade
10:58:49 - 09-May-25
Buy* 771,042 0.518p Ordinary
10:58:36 - 09-May-25
Buy* 19,267 0.519p Ordinary
08:24:31 - 09-May-25
Buy* 19,267 0.519p Ordinary
08:21:57 - 09-May-25
Buy* 1,818 0.55p Ordinary
08:21:28 - 09-May-25
See more N4 Pharma Plc trades

N4 Pharma Plc (N4P) Share Price History

Time period:
to
Date Open High Low Close Volume
8th May 2025 (Thu) 0.485 0.51 0.485 0.51 2,923,055
7th May 2025 (Wed) 0.425 0.485 0.425 0.485 9,961,050
6th May 2025 (Tue) 0.425 0.425 0.425 0.425 46,016
5th May 2025 (Mon) 0.45 0.45 0.45 0.45 0
2nd May 2025 (Fri) 0.425 0.425 0.425 0.425 13,148
1st May 2025 (Thu) 0.425 0.43 0.43 0.43 123,485
30th Apr 2025 (Wed) 0.425 0.425 0.425 0.425 4,941,450
29th Apr 2025 (Tue) 0.375 0.425 0.375 0.425 1,799,755
28th Apr 2025 (Mon) 0.375 0.375 0.375 0.375 1,904,287
25th Apr 2025 (Fri) 0.375 0.375 0.375 0.375 1,212,125
24th Apr 2025 (Thu) 0.375 0.375 0.375 0.375 676,182
23rd Apr 2025 (Wed) 0.375 0.40 0.40 0.40 735,359
22nd Apr 2025 (Tue) 0.375 0.375 0.375 0.375 1,221,225
21st Apr 2025 (Mon) 0.375 0.375 0.375 0.375 0
18th Apr 2025 (Fri) 0.375 0.375 0.375 0.375 0
17th Apr 2025 (Thu) 0.375 0.375 0.375 0.375 13,154,317
16th Apr 2025 (Wed) 0.375 0.375 0.375 0.375 5,060,511
15th Apr 2025 (Tue) 0.375 0.375 0.375 0.375 104,270
14th Apr 2025 (Mon) 0.375 0.375 0.375 0.375 653,363
11th Apr 2025 (Fri) 0.375 0.375 0.375 0.375 1,136,335
10th Apr 2025 (Thu) 0.375 0.375 0.375 0.375 2,309,993
9th Apr 2025 (Wed) 0.425 0.425 0.375 0.375 2,154,922
See more N4 Pharma Plc price history

N4 Pharma Plc (N4P) Regulatory News

Date Source Headline
29th Apr 2025 4:25 pm RNS Holding(s) in Company
29th Apr 2025 11:05 am RNS Holding(s) in Company
28th Apr 2025 2:30 pm RNS Holding(s) in Company
23rd Apr 2025 2:32 pm RNS TR-1: Standard form notification of major holdings
22nd Apr 2025 11:56 am RNS Result of General Meeting
4th Apr 2025 7:08 am RNS Posting of Circular and Notice of General Meeting
1st Apr 2025 4:08 pm RNS Placing and Subscription to raise £1,750,000
18th Feb 2025 12:34 pm RNS Holding(s) in Company
7th Feb 2025 7:00 am RNS-R Investor Webinar
27th Jan 2025 7:00 am RNS-R Investor Webinar
See more N4 Pharma Plc regulatory news

N4 Pharma Plc (N4P) Share News

UK shareholder meetings calendar - next 7 days

15th Apr 2025 14:20

Read More

AIM WINNERS & LOSERS: Velocity Composites expects to beat market view

12th Dec 2024 10:40

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More

AIM WINNERS & LOSERS: Biome warns on revenue; legal blow for LCM

4th Dec 2024 10:57

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More

EARNINGS: Metals One advances Black Schist, N4 generates revenue

24th Sep 2024 15:01

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: N4 Pharma celebrates chemistry work update on Nuvec

20th Aug 2024 11:52

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology Nuvec - Notes SRI International has successfully completed the chemistry work and shown that a fox three molecular guidance system can be added to Nuvec without altering its loading capability. Chief Executive Nigel Theobald says: "This is an exciting development for us as it clearly shows that Nuvec is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for. We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs." N4 Pharma says the next step is to show that small interfering RNA still retains its functionality in the target cell. Read More

See more N4 Pharma Plc news
FTSE 100 Latest
Value8,569.98
Change38.37

Login to your account

Forgot Password?

Not Registered